---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-067398"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:31:18.815410+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q2 net loss $4.4M; OLC FDA feedback expected Fall 2023; UNI-494 Phase 1 ongoing

## Summary
- Net loss of $4.4M ($0.29/share) in Q2 2023, up from $3.6M ($0.24) in Q2 2022 due to higher R&D and G&A costs.
- Cash and equivalents totaled $18.8M as of June 30, 2023.
- Positive OLC data published in Am J Nephrol: lowest daily dose volume vs five commercial phosphate binders.
- Expects FDA alignment feedback in Fall 2023 for OLC program; NDA submission after that.
- UNI-494 Phase 1 trial ongoing in UK; pre-IND meeting with FDA planned by year-end; IND expected in 2024.

## SEC filing metadata
- accession: 0001213900-23-067398
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023067398/0001213900-23-067398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023067398/ea183515-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-067398
- JSON: https://secwatch.observer/filing/0001213900-23-067398.json
- Plain text: https://secwatch.observer/filing/0001213900-23-067398.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $4.4 million, EPS $0.29 per share of common stock.
  - Period: the second quarter ended June 30, 2023
  - Net income: $4.4 million
  - EPS: $0.29 per share of common stock
  - Result: reported results
  source text: Net loss attributable to common stockholders for the quarter ended June 30, 2023 was $4.4 million, or $0.29 per share of common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023067398/0001213900-23-067398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.